SG144166A1 - Oligodendrocyte precursor cells and methods of obtaining and culturing the same - Google Patents
Oligodendrocyte precursor cells and methods of obtaining and culturing the sameInfo
- Publication number
- SG144166A1 SG144166A1 SG200804940-5A SG2008049405A SG144166A1 SG 144166 A1 SG144166 A1 SG 144166A1 SG 2008049405 A SG2008049405 A SG 2008049405A SG 144166 A1 SG144166 A1 SG 144166A1
- Authority
- SG
- Singapore
- Prior art keywords
- precursor cells
- methods
- oligodendrocyte precursor
- obtaining
- homogeneous population
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/395—Thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48793303P | 2003-07-18 | 2003-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG144166A1 true SG144166A1 (en) | 2008-07-29 |
Family
ID=34079394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200804940-5A SG144166A1 (en) | 2003-07-18 | 2004-07-19 | Oligodendrocyte precursor cells and methods of obtaining and culturing the same |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060172415A1 (es) |
EP (1) | EP1646711A4 (es) |
JP (1) | JP2007530001A (es) |
KR (1) | KR20060037346A (es) |
CN (1) | CN1833021A (es) |
AR (1) | AR046076A1 (es) |
AU (1) | AU2004257000B2 (es) |
BR (1) | BRPI0412715A (es) |
CA (1) | CA2532216A1 (es) |
MX (1) | MXPA05014161A (es) |
SG (1) | SG144166A1 (es) |
TW (1) | TW200510537A (es) |
WO (1) | WO2005007797A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1846578A4 (en) * | 2005-02-11 | 2010-02-10 | Elan Pharm Inc | GENE IDENTIFICATION METHODS THAT MODULATE MYELINISATION |
CN106177996A (zh) * | 2005-06-23 | 2016-12-07 | 组织基因公司 | 神经保护性化合物 |
ES2323913B1 (es) * | 2006-03-17 | 2010-05-14 | Universidad De Salamanca (Titular Al 65%) | Efecto mitogeno de sonic hedgehog (shh) sobre precursores de oligodendrocitos y su uso en enfermedades desmielinizantes. |
SG188096A1 (en) | 2008-01-30 | 2013-03-28 | Geron Corp | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
US8168433B2 (en) * | 2008-01-30 | 2012-05-01 | Corning Incorporated | Cell culture article and screening |
EP2247718B1 (en) * | 2008-01-30 | 2019-01-16 | Asterias Biotherapeutics, Inc. | Synthetic surfaces for culturing stem cell derived cardiomyocytes |
EP2355826A1 (en) * | 2008-11-07 | 2011-08-17 | The Cleveland Clinic Foundation | Compounds and methods of promoting oligodendrocyte precursor differentiation |
CN102686721B (zh) * | 2009-11-12 | 2016-02-10 | Q医疗公司 | 用于哺乳动物来源的神经胶质限制性祖细胞的扩增、鉴定、表征和效能增强的方法和组合物 |
CN101735983B (zh) * | 2009-12-29 | 2011-07-27 | 中国人民解放军第三军医大学 | 少突胶质前体细胞的分离纯化方法 |
ES2375860B8 (es) * | 2010-03-31 | 2013-06-10 | Fundación Hospital Nacional De Parapléjicos Para La Investigación Y La Integración (Fuhnpaiin) | Método para la obtención de células precursoras de oligodendrocitos. |
JP2014528706A (ja) * | 2011-08-07 | 2014-10-30 | カディマステム リミテッド | 成熟、生存及びミエリン形成に作用する薬剤を同定する方法 |
KR101409336B1 (ko) | 2012-02-15 | 2014-06-27 | 중앙대학교 산학협력단 | 희돌기교전구세포를 유효성분으로 포함하는 중추신경계 질환의 치료용 조성물 |
EP2831222B1 (en) * | 2012-03-27 | 2018-12-26 | Okinawa Institute of Science and Technology Graduate University | Neuronal culture medium and method for producing in vivo-like and enhanced synaptogenesis neuron model |
US10180423B2 (en) * | 2012-12-19 | 2019-01-15 | The Regents Of The University Of California | Micropillar arrays for assaying myelination |
CN103388007B (zh) * | 2013-07-25 | 2016-08-24 | 宗兆文 | 一种利用真皮来源的间充质干细胞制备组织工程脊髓的方法 |
JP6844953B2 (ja) * | 2015-04-22 | 2021-03-17 | 公益財団法人東京都医学総合研究所 | アルツハイマー病研究を標的にしたグリア細胞システム |
CN105062956B (zh) * | 2015-08-21 | 2018-02-09 | 北京市虹天济神经科学研究院 | 人嗅粘膜嗅鞘细胞分离、传代、冻存、分化技术 |
CN105695409B (zh) * | 2016-03-22 | 2019-09-27 | 中国人民解放军第二军医大学 | 一种裸鼹鼠少突胶质前体细胞培养方法 |
US11920155B2 (en) | 2016-03-30 | 2024-03-05 | Asterias Biotherapeutics, Inc. | Oligodendrocyte progenitor cell compositions |
WO2018053210A1 (en) * | 2016-09-14 | 2018-03-22 | Asterias Biotherapeutics, Inc. | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
CN109722418B (zh) * | 2017-10-29 | 2023-01-03 | 复旦大学 | 一种获取和纯化新生小鼠少突胶质前体细胞的方法 |
CN108624560B (zh) * | 2018-06-01 | 2022-04-08 | 南京艾尔普再生医学科技有限公司 | 一种分化培养基及少突胶质前体细胞的制备方法 |
CN113481161A (zh) * | 2021-07-30 | 2021-10-08 | 四川省医学科学院·四川省人民医院 | 一种培养基及少突胶质祖细胞的诱导培养方法以及应用 |
CN115340982A (zh) * | 2022-08-23 | 2022-11-15 | 徐州医科大学 | 一种分离并纯化新生小鼠皮质区少突胶质前体细胞的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5753506A (en) * | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
US6361996B1 (en) * | 1997-05-07 | 2002-03-26 | University Of Utah Research Foundation | Neuroepithelial stem cells and glial-restricted intermediate precursors |
US6235527B1 (en) * | 1997-11-29 | 2001-05-22 | University Of Utah Research Foundation | Lineage restricted glial precursors from the central nervous system |
US6576464B2 (en) * | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
US20040029269A1 (en) * | 2002-05-07 | 2004-02-12 | Goldman Steven A | Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells |
US7285415B2 (en) * | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
-
2004
- 2004-07-16 AR ARP040102543A patent/AR046076A1/es unknown
- 2004-07-19 MX MXPA05014161A patent/MXPA05014161A/es active IP Right Grant
- 2004-07-19 CN CNA2004800193757A patent/CN1833021A/zh active Pending
- 2004-07-19 BR BRPI0412715-3A patent/BRPI0412715A/pt not_active IP Right Cessation
- 2004-07-19 EP EP04744291A patent/EP1646711A4/en not_active Withdrawn
- 2004-07-19 KR KR1020067000833A patent/KR20060037346A/ko not_active Application Discontinuation
- 2004-07-19 CA CA002532216A patent/CA2532216A1/en not_active Abandoned
- 2004-07-19 US US10/564,819 patent/US20060172415A1/en not_active Abandoned
- 2004-07-19 TW TW093121529A patent/TW200510537A/zh unknown
- 2004-07-19 SG SG200804940-5A patent/SG144166A1/en unknown
- 2004-07-19 WO PCT/IB2004/002670 patent/WO2005007797A2/en active Application Filing
- 2004-07-19 AU AU2004257000A patent/AU2004257000B2/en not_active Expired - Fee Related
- 2004-07-19 JP JP2006520045A patent/JP2007530001A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2004257000B2 (en) | 2011-07-21 |
WO2005007797A2 (en) | 2005-01-27 |
CA2532216A1 (en) | 2005-01-27 |
BRPI0412715A (pt) | 2006-09-26 |
KR20060037346A (ko) | 2006-05-03 |
EP1646711A4 (en) | 2008-03-19 |
AU2004257000A1 (en) | 2005-01-27 |
TW200510537A (en) | 2005-03-16 |
MXPA05014161A (es) | 2006-05-25 |
CN1833021A (zh) | 2006-09-13 |
AR046076A1 (es) | 2005-11-23 |
JP2007530001A (ja) | 2007-11-01 |
US20060172415A1 (en) | 2006-08-03 |
EP1646711A2 (en) | 2006-04-19 |
WO2005007797A3 (en) | 2006-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG144166A1 (en) | Oligodendrocyte precursor cells and methods of obtaining and culturing the same | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
WO2007051038A3 (en) | Pdx1-expressing dorsal and ventral foregut endoderm | |
EP2281568A3 (en) | Uses of soluble CTLA4 mutant molecules | |
WO2005116073A3 (en) | Pdx1 expressing endoderm | |
IL157332A0 (en) | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof | |
IL145213A0 (en) | Polyurethane solutions containing allkoxysilane structural units | |
TW200637522A (en) | Skin treatment articles and methods | |
WO2007047766A3 (en) | Methods for rejuvenating cells in vitro and in vivo | |
HK1101811A1 (en) | Article, filter media and method of making the filter media | |
SG149061A1 (en) | Definitive endoderm | |
AU2001273218A1 (en) | Methods for stimulation of synthesis of synaptophysin in the central nervous system | |
AU4221399A (en) | Human cd45+ and/or fibroblast + mesenchymal stem cells | |
MX2007010045A (es) | Pirazolopirimidinas. | |
EP1917355A4 (en) | PLY-GBS MUTANT LYSINE | |
HK1087351A1 (en) | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit | |
GB0423356D0 (en) | Therapeutic agents | |
EP3031326A3 (en) | Bone marrow-derived mesenchymal stem cells as a source of neural progenitors | |
MY109486A (en) | Method employing type ii endoglycosidase | |
WO2006001911A3 (en) | Crystal structure of the hepatocyte growth factor beta chain and methods of use | |
WO2004087066A3 (en) | Hif-1 inhibitors | |
SI1147088T1 (sl) | 6-arilfenantridini s PDE-IV inhibirajoco aktivnostjo | |
AU2001253495A1 (en) | Treating graft rejection with ccr5 inhibitors | |
MXPA03010406A (es) | Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd. | |
UA83203C2 (uk) | Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами |